

Epidermal growth factor receptor antagonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/E14A900BF8D2EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: E14A900BF8D2EN

Abstracts

This report can be delivered to the clients within 72 hours

DelveInsight's, "Epidermal Growth Factor Receptor Antagonists - Pipeline Insight, 2022" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Epidermal Growth Factor Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Epidermal Growth Factor Receptor Antagonists Understanding

Epidermal Growth Factor Receptor Antagonists: Overview

Epidermal growth factor (EGF) is a 53-amino-acid cytokine which is proteolytically cleaved from a large integral membrane protein precursor. EGF acts to stimulate growth of epithelial cells, accelerates tooth eruption and eyelid opening in mice, inhibits gastric acid secretion and is involved in wound healing.

Function - The epidermal growth factor family of receptor tyrosine kinases (ErbBs) plays essential roles in regulating cell proliferation, survival, differentiation and migration. The ErbB receptors carry out both redundant and restricted functions in mammalian

development and in the maintenance of tissues in the adult mammal. Loss of regulation of the ErbB receptors underlies many human diseases, most notably cancer.

Epidermal Growth Factor Receptor Antagonists - EGFR inhibitor was the first agent developed as a target cancer therapy. Two classes of EGFR inhibitors are in current use: the monoclonal antibodies that target the extracellular ligand-binding domain and small-molecule tyrosine kinase inhibitors (which target intracellular domain. EGFR inhibitors have been approved for the treatment of metastatic non-small-cell lung cancer, colorectal cancer, pancreatic cancer, and squamous cell carcinoma of the head and neck. When the expression of EGFR is decreased, inhibition of downstream signaling occurs in malignant tumor cells. This results in inhibition of metastasis, growth, proliferation, differentiation, and angiogenesis and causing apoptosis of cancer cells.

Epidermal Growth Factor Receptor Antagonists Emerging Drugs Chapters

This segment of the Epidermal Growth Factor Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Epidermal Growth Factor Receptor Antagonists Emerging Drugs

Nazartinib: Novartis Oncology

Novartis Oncology (previously Novartis) is developing nazartinib (formerly EGF 816), a third generation mutant-selective tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), for the treatment of solid malignancies, with a focus on non-small cell lung cancer. Nazartinib is a covalent mutant-selective EGFR inhibitor, with K_i and K_{inact} of 31 nM and 0.222 min⁻¹ on EGFR(L858R/790M) mutant, respectively. Upon oral administration, nazartinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. Currently, it is in phase 3 stage of development for the treatment of Non-small cell lung cancer.

Zorifertinib: AstraZeneca

Zorifertinib (AZD-3759) is an oral inhibitor of both wild-type and mutant EGFR with IC50 values in nanomolar range. The drug was discovered by AstraZeneca for the treatment of non-small-cell lung cancer with CNS metastases. AZD-3759 can penetrate the blood-brain barrier and was confirmed to be effective in vitro with NSCLC cell lines as well as in mouse model of brain metastases.

Further product details are provided in the report.....

Epidermal Growth Factor Receptor Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Epidermal Growth Factor Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Epidermal Growth Factor Receptor Antagonists

There are approx. 30+ key companies which are developing the Epidermal Growth Factor Receptor Antagonists. The companies which have their Epidermal Growth Factor Receptor Antagonists drug candidates in the most advanced stage, i.e. phase III include, Novartis Oncology.

Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Epidermal Growth Factor Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Epidermal Growth Factor Receptor Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Epidermal Growth Factor Receptor Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Epidermal Growth Factor Receptor Antagonists drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Epidermal Growth Factor Receptor Antagonists R&D. The therapies under development are focused on novel approaches for Epidermal Growth Factor Receptor Antagonists.

Epidermal Growth Factor Receptor Antagonists Report Insights

Epidermal Growth Factor Receptor Antagonists Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Epidermal Growth Factor Receptor Antagonists Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Epidermal Growth Factor Receptor Antagonists drugs?

How many Epidermal Growth Factor Receptor Antagonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Epidermal Growth Factor Receptor Antagonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Epidermal Growth Factor Receptor Antagonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Epidermal Growth Factor Receptor Antagonists and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Novartis Oncology

AstraZeneca

Voronoi

Blueprint Medicines

Symphogen

Hutchison Medipharma

Beta Pharma

Checkpoint Therapeutics

InventisBio

XuanZhu Pharma

Allist Pharmaceuticals

ACEA Therapeutics

Astellas Pharma

Sunshine Lake Pharma

Hangzhou ACEA Pharmaceutical Research

Black Diamond Therapeutics

Zentalis Pharmaceuticals

Glycotope

Sinocelltech

Pfizer

Cullinan Oncology

Merus

ARIAD Pharmaceuticals

Jiangsu Hengrui Medicine

Tianjin Hemay Biotech

Shanghai Henlius Biotech

Sichuan Kelun Pharmaceutical Research Institute

Key Products

Nazartinib

Zorifertinib

ORIC 114

BLU 945

Futuximab/modotuximab

Epitinib

Rezivertinib

Olafertinib

D 0316

Pirotinib

Alflutinib

Abivertinib

Osimertinib

Erlotinib

Gefitinib

Larotinib

Avitinib

BDTX 189

ZN e4

Tomuzotuximab

SCT 200

Dacomitinib

CLN 081

MCLA 129

Mobocertinib

Pyrotinib

PB 357

Hemay 022

Cetuximab biosimilar

KL 140

Contents

Introduction

Executive Summary

Epidermal Growth Factor Receptor Antagonists: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Epidermal Growth Factor Receptor Antagonists – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Epidermal Growth Factor Receptor Antagonists companies' collaborations, Licensing, Acquisition -Deal Value Trends

Epidermal Growth Factor Receptor Antagonists Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Nazartinib: Novartis Oncology

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Pirotinib: XuanZhu Pharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis

BLU 945: Blueprint Medicines

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

ORIC 114: Voronoi

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Epidermal Growth Factor Receptor Antagonists Key Companies**Epidermal Growth Factor Receptor Antagonists Key Products****Epidermal Growth Factor Receptor Antagonists- Unmet Needs****Epidermal Growth Factor Receptor Antagonists- Market Drivers and Barriers****Epidermal Growth Factor Receptor Antagonists- Future Perspectives and Conclusion****Epidermal Growth Factor Receptor Antagonists Analyst Views****Epidermal Growth Factor Receptor Antagonists Key Companies****Appendix**

I would like to order

Product name: Epidermal growth factor receptor antagonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/E14A900BF8D2EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E14A900BF8D2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970